WASHINGTON, 28 October 2026 — The US Food and Drug Administration (FDA) has updated the prescribing information for the cholesterol drug Repatha (evolocumab) so that it now covers reducing the risk of a first major cardiovascular event in high-risk adults who have never had a heart attack or stroke, according to the revised label summarised on 28 October 2026.
The FDA recorded approval of an efficacy supplement for Repatha on 9 October 2026, an approval record shows. The revised October prescribing information describes VESALIUS-CV, a large randomised trial in high-risk adults without a previous heart attack or stroke, and states that the drug's indication now includes reducing major cardiovascular events in adults at increased risk, including ischaemia-driven arterial revascularisation.
Illustration: A doctor holding a glowing heart, representing prevention of a first heart attack or stroke.
What Happened
Repatha, made by Amgen, is a PCSK9 inhibitor: a monoclonal antibody that lowers low-density lipoprotein (LDL) cholesterol, often called "bad" cholesterol, by blocking a protein that otherwise prevents the liver from clearing LDL from the blood. It was first approved in 2015, and in August 2025 the FDA had already broadened its approved use to include adults at increased risk for major adverse cardiovascular events due to uncontrolled LDL cholesterol, removing a prior requirement for a diagnosed cardiovascular disease.
The October 2026 label update goes further by anchoring that broader use in outcomes evidence. According to the prescribing information as summarised by the AbangeLabs HTA Intelligence digest on 28 October, VESALIUS-CV was a double-blind randomised controlled trial involving 12,206 adults, comparing evolocumab with placebo on top of background care, with a median follow-up of 55 months — nearly five years. For the primary composite outcome of coronary heart disease death, heart attack or ischaemic stroke, the hazard ratio was 0.75, with a 95 percent confidence interval of 0.65 to 0.86. In plain terms, that corresponds to roughly a 25 percent lower relative rate of those events in the evolocumab group over the trial period. A second primary composite, which also included any ischaemia-driven arterial revascularisation, had a hazard ratio of 0.81 (95 percent confidence interval 0.73 to 0.89).
Those numbers describe relative differences, and they need context. A hazard ratio below 1 means fewer events in the treatment group, but it does not say how large a given individual's absolute risk was to begin with, nor does it remove the need for the rest of cardiovascular prevention — blood pressure control, not smoking, diabetes management, diet and exercise. The label change is also not a recommendation that every adult with raised cholesterol should receive the drug. It applies to adults at increased risk, as judged by their clinician, and the drug is given by injection, typically every two weeks, which is a bigger commitment than a daily statin tablet for many patients.
Background
Heart attacks and strokes remain among the world's leading causes of death, and LDL cholesterol is one of the most firmly established modifiable risk factors. Statins, which have been available for decades, lower LDL substantially and reduce cardiovascular events, and they remain the foundation of cholesterol treatment. But some patients cannot reach their LDL goals on the maximum tolerated statin dose, and others cannot tolerate statins at all. That gap is where non-statin therapies, including PCSK9 inhibitors such as evolocumab and alirocumab, and newer options such as inclisiran, have found their role — as additions to, not replacements for, statin therapy in most cases.
Earlier PCSK9 outcome trials mostly studied secondary prevention: patients who had already had a heart attack, stroke or established atherosclerotic disease. VESALIUS-CV was different because it focused on primary prevention — people at high risk who had not yet had an event. Trial coverage presented at cardiology meetings in 2025 described a population with elevated LDL cholesterol but no prior heart attack or stroke, most of whom were already receiving lipid-lowering therapy. That design is what makes the October 2026 label update notable: it extends outcomes-based evidence into the group where prevention, if it works, averts a first catastrophe rather than a repeat one.
Illustration: Cholesterol buildup clearing from an artery, representing LDL lowering.
There is also a cost and access dimension that the label update does not resolve. PCSK9 inhibitors are far more expensive than generic statins, and access has historically depended on insurance coverage, prior authorisation and documented LDL levels despite statin therapy. Amgen has reported that Repatha has been used by approximately 9 million patients globally and is approved in 75 countries. Broader indications can expand the eligible population, but whether health systems and insurers pay for that expansion — and for whom — will be decided in coverage policies and guidelines, not in the label itself.
Why It Matters
For patients at high cardiovascular risk who have not yet had an event, the label change matters because it changes the conversation with their doctor. Previously, the strongest outcomes evidence for PCSK9 inhibitors sat largely in secondary prevention; a patient asking "will this actually prevent my first heart attack?" could only be pointed to cholesterol-lowering data and extrapolation. Now, clinicians can point to a randomised trial in a primary-prevention population, with nearly five years of median follow-up, showing fewer first major events. That is a firmer basis for shared decision-making, even though individual benefit still depends on individual risk.
For doctors and guideline writers, the update adds weight to intensive LDL lowering in high-risk patients. Trial commentators have noted that VESALIUS-CV supports lowering LDL to around 40 mg/dL in such patients, well below the levels many patients currently achieve. The 2026 cholesterol guideline discussion likewise presents PCSK9 monoclonal antibodies as an option for patients who do not reach LDL goals on maximally tolerated statin therapy. Guidelines move more slowly than labels, so the practical question now is how quickly professional societies incorporate the primary-prevention outcomes data into recommendations — and how they balance benefit against cost and injection burden.
Illustration: A medicine auto-injector pen beside a heart health leaflet, representing long-term prevention treatment.
What Happens Next
The immediate next step is clinical, not regulatory: doctors, pharmacists and patients discussing whether the updated indication changes individual treatment plans. Patients already taking Repatha need no action on the basis of the label alone, and patients who are not taking it should not start or stop any cholesterol medicine because of a news report. Decisions about adding a PCSK9 inhibitor involve LDL levels, overall cardiovascular risk, other conditions, cost and personal preference, and they belong in a consultation, not a headline. This article is general information only and is not medical advice.
Guideline committees and payers are next: expect guidance updates and coverage decisions citing VESALIUS-CV, with attention to which high-risk subgroups benefit most. Real-world studies will also matter: trial participants are monitored more closely than ordinary patients, so how adherence, persistence and outcomes look in routine practice — including for the every-two-week injection schedule — will shape how widely the broader indication is actually used.
Longer term, researchers will watch whether the primary-prevention benefit holds up in subgroups and over longer follow-up, and whether competing approaches — including oral PCSK9-targeting drugs and twice-yearly injections in development — change the convenience and cost equation. For now, the October 2026 label update stands as a meaningful, evidence-based widening of who can be offered one of cardiology's most potent cholesterol-lowering tools — before, rather than after, the first heart attack or stroke.
Sponsored: explore today's featured sponsored offers
FAQ
What is Repatha, and what does it do?
Repatha (evolocumab), made by Amgen, is a PCSK9 inhibitor — a monoclonal antibody given by injection that lowers LDL ("bad") cholesterol by helping the liver clear it from the blood. It is usually added to statin therapy, not used instead of it.
What changed in the FDA label in October 2026?
The FDA recorded approval of an efficacy supplement on 9 October 2026. The revised prescribing information now includes reducing major cardiovascular events in adults at increased risk, including ischaemia-driven arterial revascularisation, based on the VESALIUS-CV trial in people without a prior heart attack or stroke.
How large was the VESALIUS-CV trial, and what did it find?
According to the prescribing information, the double-blind randomised trial involved 12,206 adults with a median follow-up of 55 months. The hazard ratio for coronary heart disease death, heart attack or ischaemic stroke was 0.75, and 0.81 when ischaemia-driven revascularisation was also included.
Does this mean everyone with high cholesterol should take Repatha?
No. The indication covers adults at increased risk, as judged by their clinician, and the drug is an injectable biologic that costs far more than generic statins. Treatment decisions depend on individual risk, LDL levels, other conditions, cost and personal preference.
Is this article medical advice?
No. This article is general information about a regulatory update and trial results. It is not medical advice, and anyone considering a change to cholesterol treatment should discuss it with their own doctor or pharmacist.
Sources
- US Food and Drug Administration prescribing information for Repatha (evolocumab), revised October 2026, as summarised by AbangeLabs HTA Intelligence, "Repatha efficacy update documents outcomes before a first heart attack or stroke", 28 October 2026.
- FDA approval record for Repatha (Amgen, application 125522, supplement 47), status changed to approval on 9 October 2026, reported 12 October 2026.
- Amgen via PR Newswire, "Amgen's Repatha reduces risk of death in patients at high risk for a first heart attack or stroke", 2026 (August 2025 FDA broadening; August 2026 European Commission expanded indication based on VESALIUS-CV).
- Healio, "Evolocumab lowers risk for first major cardiovascular events", November 2025 (VESALIUS-CV trial population and design).
Comments
Post a Comment